Most B2B research is designed to feel safe. It prioritizes representativeness. It seeks consensus. It works hard to make sure every segment is covered, every voice counted, every finding defensible in a room full of skeptics. Those goals make sense if the primary risk you’re managing is organizational discomfort. They make far less sense if you’re trying to decide what to build, what to cut, or where to place a meaningful bet. Representativeness is a statistical virtue, not a

Product teams talk about risk constantly. They track it, mitigate it, escalate it, and reference it in nearly every decision discussion. What they rarely do is define it. As a result, “risk” becomes a vague proxy for unease. A catch-all label applied to disagreement, uncertainty, incomplete information, or the simple fear of being wrong. When that happens, risk stops being a tool for better decisions and starts functioning as a brake on them. Most stalled product decisions do